Navigation Links
Pharsight to Present at ROeS Seminar in Bern, Switzerland on September 10 & 11, 2007
Date:9/4/2007

Dr. Andreas Krause to Present on Statistical Considerations for Model Selection and Bias; Dr. Klaas Prins to Present on Modeling and Simulation

Using Metadata

MOUNTAIN VIEW, Calif., Sept. 4 /PRNewswire-FirstCall/ -- Pharsight Corporation (OTC Bulletin Board: PHST), a leading provider of software and strategic services for optimizing clinical drug development, today announced that Pharsight senior scientists will deliver two presentations to biopharmaceutical industry statisticians attending the annual ROeS Seminar (Austrian-Swiss Region of the International Biometric Society), to be held in Bern, Switzerland on September 9-13, 2007. Andreas Krause, Ph.D., senior biostat-istician, Strategic Consulting Services, will present a model-based approach to assess clinical study data for potentially confounding effects; Klaas Prins, Ph.D., senior scientist, Strategic Consulting Services, will present methods for extracting and integrating public-source scientific literature in modeling and simulation analyses.

Drs. Krause and Prins will present applied case studies at two ROeS seminar sessions, each of which will provide a forum for pharmaceutical scientists from industry and academia to have a collaborative exchange on model-based approaches. Pharsight's two presentations are:

-- September 10: Modeling and simulation to adjust p-values in presence

of a regression to the mean effect.

Dr. Krause will present this case study as part of a dedicated

conference session on selection procedures and bias. The session will

include applied examples of statistical methods to enable model-based

drug development, and will describe research on how modeling and

simulation has been used to analyze and monitor clinical information.

-- September 11: Modeling and simulation using metadata: away from

inventing the wheel again.

Dr. Prins will present this case study as part of a dedicated

conference session on methods in meta analysis. The session will

include applied examples of modeling and simulation in several

therapeutic areas, and will describe research on how models based on

subject-level data and summary trial data have been used to predict

drug candidate performance, capture development knowledge, and support

the design of future clinical studies.

Additional information can be found at http://www.meduniwien.ac.at/ROeS/

"Model-based drug development continues to show value for optimizing drug therapy and for improving the confidence of drug development decisions," said Shawn O'Connor, president, CEO, and chairman of Pharsight. "Drug development can benefit from the application of novel statistical methods and quantitative models to simulate expected clinical responses of new compounds, to support critical program strategies and to enhance study design decisions. Pharsight is pleased to participate at the annual ROeS Seminar, and to exchange information with industry colleagues on the strategic use of modeling and simulation."

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com. Registered Trademarks and Trademarks

Pharsight is a registered trademark of Pharsight Corporation.


'/>"/>
SOURCE Pharsight Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... May 06, 2016 , ... Crucial Life Sciences ... Version 4.1, greatly improves performance of the platform. In particular, Version 4.1 boosts ... volumes of data to be collected on a per patient basis. Clinical Studio ...
(Date:5/5/2016)... ... May 05, 2016 , ... American Process, Inc. (API) announced ... Patent Nos. 9,322,133 and 9,322,134, to API and its affiliated companies for BioPlus® ... hydrophobic nanocellulose compositions. In addition to these patents and U.S. Patent No. ...
(Date:5/4/2016)... ... May 05, 2016 , ... CereScan, the ... National Stroke Association during National Stroke Awareness Month in May. An infographic ... throughout the month. CereScan will donate $1 up to a maximum of ...
(Date:5/4/2016)... , May 4, 2016  Bayer today announced ... compound Stivarga ® (regorafenib) tablets for the ... has met its primary endpoint of a statistically ... RESORCE, evaluated the efficacy and safety of regorafenib ... after treatment with sorafenib. The safety and tolerability ...
Breaking Biology Technology:
(Date:3/14/2016)... 14, 2016 http://www.apimages.com ) ... --> - Renvoi : image disponible via AP ... --> --> DERMALOG, le leader ... nouveaux lecteurs d,empreintes digitales pour l,enregistrement des réfugiés ... utilisé pour produire des cartes d,identité aux réfugiés. ...
(Date:3/10/2016)... 10, 2016   Unisys Corporation (NYSE: UIS ... (CBP) is testing its biometric identity solution at the ... to help identify certain non-U.S. citizens leaving the country. ... designed to help determine the efficiency and accuracy of using ... and will run until May 2016. --> ...
(Date:3/8/2016)... , March 8, 2016   Valencell , ... today announced it has secured $11M in Series ... Tech, a new venture fund being launched by ... participation from existing investors TDF Ventures and WSJ ... to continue its triple-digit growth and accelerate its ...
Breaking Biology News(10 mins):